Podcasts about mmr

South Carolina parents are mobilizing as two conflicting vaccine bills hit the legislature. One would ban religious exemptions for the MMR vaccine, while another protects children under 24 months from mandates. Tara and Amanda Hovis break down the science, the politics, and the fight for parental rights.

Tara covers two explosive topics today: South Carolina's vaccine legislation threatening parental rights, and why President Trump's strike on Iran was legally and strategically justified. From MMR debates to AUMFs and imminent threats, this episode breaks down the facts the mainstream media won't cover.

This week's stories: Sinclair's This Is the Test: Are we about to see age reversal in humans? At the World Governments Summit 2026 in Dubai, Harvard geneticist David Sinclair told world leaders that ageing could soon be reversible and said the first human clinical trials of epigenetic reprogramming therapies are moving forward. The core idea is that ageing is partly an information problem, how cells read DNA, not just cumulative damage, and that partial reprogramming could restore youthful function without turning tissues into tumors. Dave frames this as a rare binary moment for longevity: either early, localized human trials (starting with tightly controlled tissue targets like the eye) show meaningful functional rejuvenation with acceptable safety, or the field has to recalibrate fast. Either way, the next couple of years will heavily influence where money, regulators, and serious researchers place their bets. • Sources: – World Governments Summit: https://www.worldgovernmentssummit.org/media-hub/news/detail/ageing-could-soon-be-reversible-says-harvard-scientist-at-wgs-2026 – NAD / Life Biosciences coverage: https://www.nad.com/news/fda-greenlights-life-biosciences-human-study-setting-up-pivotal-test-for-aging-theory-from-harvards-david-sinclair AlphaFold 4 in a locked box: DeepMind's private AI drug design engine Isomorphic Labs, DeepMind's drug discovery company, unveiled a proprietary drug design engine that outside scientists are comparing to an AlphaFold 4 moment, but for designing drugs, not just predicting structures. The big shift is that this system is closed: no public weights, no open database, and access appears to flow through partnerships with pharma companies. Dave breaks down why that matters for the longevity world: if AI makes early discovery cheaper and faster, we might see more serious shots on ageing targets over the next decade, but a closed model can also mean less transparency, bigger IP moats, and no guarantee that faster discovery leads to cheaper drugs. • Sources: – Nature: https://www.nature.com/articles/d41586-026-00365-7 – Isomorphic Labs: https://www.isomorphiclabs.com/articles/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier Peptides in the freezer: El Mencho's anti aging stash and the dark side of wellness After reports and images from the final hideout linked to Jalisco New Generation Cartel leader Nemesio Oseguera Cervantes (El Mencho), coverage highlighted a detail that feels uncomfortably familiar to anyone in the modern wellness internet: injectable vials stored in a freezer with a schedule attached, including Tationil Plus, a glutathione based injectable marketed in some places for “cellular health,” cosmetic effects, and anti ageing. Dave uses the absurdity as a narrative wedge, not cartel gossip, to talk about how normalized gray market injectables have become, and how marketing (“detox,” “cellular reset”) often outruns evidence and safety. The segment pivots into a practical filter: which compounds are real therapeutics under medical supervision, and which are expensive folklore with sourcing risk and unknown long term downsides. • Sources: – New York Post: https://nypost.com/2026/02/25/world-news/inside-the-luxurious-love-nest-where-mexican-drug-lord-el-mencho-spent-his-final-days/ – Sky News (Reuters photos referenced): https://news.sky.com/story/inside-the-mexican-villa-where-feared-drug-lord-el-mencho-spent-final-hours-13511954 – Reuters photo gallery: https://www.reuters.com/pictures/el-menchos-last-hideout-inside-villa-where-cartel-leader-spent-final-hours-2026-02-25/W7DK5WEXS5IMLLZQO2P3CXGXFM The disease we thought was dead: measles comes roaring back Measles cases have surged in early 2026, with reporting citing at least 588 cases in the U.S. by late January, already more than many full year totals, and additional updates showing continued acceleration into February. Dave reframes this as a healthspan floor issue: you can argue about peptides and mitochondria all day, but measles is so contagious that once community immunity drops, outbreaks move fast and hit the most vulnerable first, especially infants and immunocompromised people. He also flags the systems problem: many clinicians have never seen measles, which increases the odds of delayed recognition and wider exposure in waiting rooms. The actionable move is boring and high ROI: verify MMR status for you and your family and close gaps before outbreaks get closer to home. • Sources: – AMA Morning Rounds (Week of Feb. 2, 2026): https://www.ama-assn.org/about/publications-newsletters/top-news-stories-ama-morning-rounds-week-feb-2-2026 – ABC News (CDC case count coverage): https://abcnews.com/Health/588-us-measles-cases-reported-january-cdc/story?id=129699078 – CIDRAP (case tracking context): https://www.cidrap.umn.edu/measles/us-measles-cases-soar-588-so-far-year-south-carolina-confirms-58-new-infections DC vs your health: Trump's State of the Union health reset President Donald Trump's 2026 State of the Union included a cluster of healthcare themes that function as a directional signal for agencies and payers this year, including drug pricing rhetoric, price transparency, and broader coverage and affordability framing. Dave translates the politics into a practical heuristic for biohackers: federal posture quietly determines what becomes easy versus painful to access in the legitimate system, from GLP 1 coverage rules and prior auth behavior to how friendly the environment is for telehealth, at home diagnostics, and eventually whatever “real longevity medicine” looks like. You do not need every policy detail in a weekly rundown, just the weather report: reimbursement and enforcement trends shape what stays niche, what scales, and what gets friction. • Sources: – Advisory Board: https://www.advisory.com/daily-briefing/2026/02/25/health-policy-roundup – Healthcare Dive: https://www.healthcaredive.com/news/trump-state-of-the-union-healthcare-2026/812962/ – This Week in Public Health analysis: https://thisweekinpublichealth.com/blog/2026/02/25/the-2026-state-of-the-union-what-it-means-for-health-and-public-health/ All source links are provided for direct access to the original reporting and research. This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on circadian biology, neurodegeneration signals, cognitive training, caffeine strategy, and supplement regulation. Host Dave Asprey connects emerging science, behavioral data, and policy shifts into practical frameworks you can use to build a resilient, adaptable health stack. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: David Sinclair age reversal, epigenetic reprogramming therapy, Yamanaka factors OSK, Life Biosciences clinical trial, human rejuvenation trial 2026, biological age reset, longevity breakthrough news, DeepMind Isomorphic Labs, AlphaFold 4 drug design, AI drug discovery engine, geroprotective drug development, peptide gray market risks, injectable glutathathione Tationil Plus, GLP-1 regulation FDA warning, wellness industry regulation, measles outbreak 2026 US, MMR vaccine status adults, vaccine trust public health, health policy 2026 State of the Union, GLP-1 access and reimbursement, telehealth longevity care, biohacking news, anti-aging research update Thank you to our sponsors! Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 0:00 - Introduction 0:30 - Story #1: David Sinclair 2026 2:13 - Story #2: Google Drug Discovery 3:48 - Story #3: El Mencho Biohacking5:30 - Story #4: Measles Outbreak 6:51 - Story #5: Trump State of the Union 8:00 - Weekly Roundup 9:10 - Closing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Broadcast from KSQD, Santa Cruz on 2-26-2026: Dr. Dawn opens with an urgent measles advisory, noting the virus has an R-value of 15 compared to COVID's peak of 5, with South Carolina reporting over 1,000 cases. She recommends those who received only one MMR shot—particularly people now in their 60s—get an immune titer blood test, as protection declines after 40-50 years. Measles can cause "immune amnesia" destroying immunity to other pathogens, and rarely leads to fatal subacute sclerosing panencephalitis years later. Dr. Dawn criticizes Quest Labs' cholesterol reporting, which flags average levels as "moderate risk" with alarming red H markers even when values fall within their own stated normal ranges. She explains this creates unnecessary panic and pushes patients toward statins based on outdated 2008-2012 guidelines, when cardiology has since recognized that cholesterol can be too low. An emailer asks how an EKG can detect a past heart attack from "jagged lines." Dr. Dawn explains that each spike represents electrical signals moving toward or away from electrode pads, and a 12-lead EKG views the heart from multiple angles—smaller-than-expected spikes in specific leads indicate dead or damaged heart muscle. She urges everyone to learn CPR and AED use, which more than doubles survival chances. An emailer reports that food tastes strong on the first bite but becomes tasteless thereafter. Dr. Dawn identifies numerous medications causing taste changes including calcium channel blockers, beta blockers, statins, diuretics, and even acetaminophen. She also highlights zinc—both deficiency and toxicity above 40mg daily can impair taste, noting a zinc nasal spray was pulled from market after causing smell loss. An emailer asks about Prenuvo full-body MRI scans costing $499-1,000. Dr. Dawn cautions that while Prenuvo found 22 cancers in 1,000 people scanned, 1 in 20 scans requires follow-up biopsy and more than half are false positives—leading to stress, expense, and potential complications from unnecessary procedures. An emailer asks about seed oils after reading a Johns Hopkins article defending them. Dr. Dawn distinguishes fruit oils (olive, avocado) from industrially-extracted seed oils requiring hexane solvent, a neurotoxin that may leave residues despite claims of evaporation. She cites a BMJ study showing coconut oil raised HDL (good cholesterol) while matching olive oil's LDL impact, and recommends cold-pressed oils while avoiding hexane-extracted products, especially for infants.

Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02958      Timestamps ·       00:00 – 02:15 Introduction and Overview ·       02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma ·       08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma ·       10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma ·       14:40 – 18:03 First-line treatment for ESCC ·       18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC ·       22:05 – 24:38 Importance of guideline ·       24:39 – 27:45 Outstanding questions and future research   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In the second part of this 20-Minute Health Talk podcast with Peter Hotez, MD, pediatrician, scientist and global health advocate, the conversation with host Chethan Sathya, MD, shifts to the front lines of health care. Dr. Hotez offers practical advice for clinicians and the public on navigating medical misinformation and myths, such as "turbo cancers.” He also reveals yet another good reason to get your Covid and flu shots — to protect your heart. As he explores the critical public health importance of childhood vaccines like the MMR and Hepatitis B, Dr. Hotez explains the real-world consequences of declining vaccination rates. Finally, he offers his frank assessment of the political and financial forces driving the anti-science movement and how to rebuild public trust. This is Part 2 of this series. Listen to Part 1 About Northwell Health Northwell is New York State's largest healthcare provider and private employer, with 28 hospitals, 890 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit our career site and explore our many opportunities. Watch more episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. 

En el año 2000 el sarampión había sido oficialmente erradicado en Estados Unidos, gracias a que un alto porcentaje de la población recibía la denominada vacuna MMR contra la rubeola, las paperas y el sarampión. 26 años más tarde, la situación ha cambiado. En lo que llevamos de año se han registrado más de 900 casos de sarampión en distintos estados y según el Centro para el Control de Enfermedades del país, en dos meses ya llevan un cuarto de todos los casos registrados en 2025. Hablamos con Flor Muñoz, profesora adjunta de pediatría, enfermedades infecciosas y virología molecular y microbiología en la Facultad de Medicina de Baylor y el Hospital Infantil de Texas en Houston.Escuchar audio

Send Zorba a message!Zorba's thoughts on why measles (a virus we had nearly eradicated) is making a comeback, and how you can protect yourself and loved ones.(recorded February 19, 2026)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

Send Zorba a message!Zorba's thoughts on why measles (a virus we had nearly eradicated) is making a comeback, and how you can protect yourself and loved ones.(recorded February 19, 2026)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

Scott and Dan welcome Dr. Heather Armstrong for a wide-ranging conversation on the gut–brain connection and its growing relevance for first responder health. Dr. Armstrong explains how the research team—working closely with Andrew Martin and frontline agencies—is uncovering meaningful links between gut health, sleep, physiology, and mental health. Early data suggests first responders are experiencing poorer overall health across multiple biological systems compared to the general population, reinforcing the need for earlier, more personalized interventions. The Better First Responders initiative continues to expand and is, in Dr. Armstrong's words, only just getting started. While current efforts remain focused locally, discussions are underway to broaden participation across provinces and into North America through emerging international partnerships. Who Can Participate The study has now opened its doors widely across the first responder community. This includes:     •    Police services     •    Fire services (including wildland and community fire)     •    Paramedics     •    Correctional officers     •    Security personnel and related first response roles The team emphasized that correctional officers are absolutely considered part of the first responder community and that Andrew Martin has strongly advocated for their inclusion. From a research standpoint, larger groups with similar schedules and job demands make statistical analysis easier and more powerful. However, the study remains wide open—even smaller groups or individuals are encouraged to participate, as every data point helps build the broader picture. Practical, Participant-Focused Research A central theme of the episode is sustainability. Rather than recommending overwhelming lifestyle overhauls, the research focuses on small, realistic changes that can create meaningful health improvements without adding stress to already demanding careers. Transparency is another key differentiator. Participants receive their own biosampling results—including microbiome and blood analyses—along with plain-language explanations. Despite the significant cost of this work (approximately $12,000 per participant), the team is committed to ensuring first responders understand their own biology and health standing. The researchers also maintain an open-door policy, actively inviting feedback from first responders about what should be studied next. Call to Action Importantly, individuals do not need to wait for their organization to sign on. Any eligible first responder can reach out directly and begin the intake process. Interested participants can:     •    Search the emergency responder MMR in GSI study title     •    Visit the program website     •    Connect via Facebook or Instagram     •    Contact Team Manager John Jenvo (details available through the program) Bottom line: This is collaborative, transparent research designed with first responders in mind—and the work to improve long-term health outcomes is still gaining momentum.Become a supporter of this podcast: https://www.spreaker.com/podcast/just-us-on-justice-and-other-things--5542256/support.

This week on The Health Advocates, we unpack a series of developments that signal a pivotal moment in U.S. health policy. The FDA has refused to review Moderna’s new mRNA-based flu vaccine, raising questions about regulatory standards and the future of vaccine innovation. At the same time, the Trump administration has launched TrumpRx, a new prescription drug discount platform that promises savings but faces scrutiny over its scope and real-world impact.We also examine new polling showing declining confidence in flu, COVID-19, and MMR vaccines, and the growing legal battle over changes to the federal childhood vaccine schedule. With public trust, regulatory rigor, and patient access all in play, this episode breaks down what these headlines mean for patients — and why clarity and credible science matter more than ever. Contact Our HostSteven Newmark, Chief of Policy at GHLF: snewmark@ghlf.orgA podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF.We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.orgListen to all episodes of The Health Advocates on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

On this Charlotte Talks, the challenges faced by pediatricians in a world of vaccine resistance. The number of measles cases in South Carolina has risen to 950. It grows almost daily and is entirely preventable if children are given the MMR vaccine for measles, mumps and rubella. Pediatricians are advocating for those vaccines, but some parents are refusing. We look at this phenomenon, its impact on pediatricians, and what's at stake.

Host: Brian P. McDonough, MD, FAAFP Guest: Christopher T. Chen, MD What if a simple blood draw could reveal whether a patient is responding to treatment before surgery? That question is at the heart of a study presented at the 2025 ESMO Congress, which investigated neoadjuvant immune checkpoint blockade in mismatch-repair-proficient (MMR-p) colon cancer. In addition to confirming that combination immunotherapy prior to surgery is a safe and feasible approach, the study also found that circulating tumor DNA (ctDNA) levels correlated with both tumor burden and early treatment response. Joining Dr. Brian McDonough to unpack these insights is Dr. Christopher Chen, Assistant Professor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.

Host: Brian P. McDonough, MD, FAAFP Guest: Christopher T. Chen, MD What if a simple blood draw could reveal whether a patient is responding to treatment before surgery? That question is at the heart of a study presented at the 2025 ESMO Congress, which investigated neoadjuvant immune checkpoint blockade in mismatch-repair-proficient (MMR-p) colon cancer. In addition to confirming that combination immunotherapy prior to surgery is a safe and feasible approach, the study also found that circulating tumor DNA (ctDNA) levels correlated with both tumor burden and early treatment response. Joining Dr. Brian McDonough to unpack these insights is Dr. Christopher Chen, Assistant Professor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.

Trek ha sido la principal protagonista de este episodio, y no solo porque haya incorporado a su catálogo la nueva Charter+, una e-bike tan válida para moverte por la ciudad como para disfrutar de los caminos, y con precios bastante interesantes, sino también por las imágenes que hemos podido ver en una de las primeras competiciones de la temporada... y que anuncian la llegada de un nuevo modelo de XC para la marca de Wisconsin. Una bicicleta que, por lo que sabemos hasta ahora, emplearía un sistema monopivote de suspensión trasera, con recorridos que la situarían entre la Supercaliber y la TopFuel, ocupando un espacio que hasta ahora se encontraba un poco 'huérfano' dentro de la marca, y que muchos bikers estaban demandando. Además de Trek, Vittoria también ha sido protagonista estos días, pues la marca italiana ha dejado ver en la feria británica iceBike 2026 un prototipo de su neumático Peyote XC Race... en 32'' pulgadas. Hemos hablado con la marca directamente y te contamos los detalles del desarrollo que están siguiendo, con el objetivo de ponerlo en el mercado en 2027. Nos hacemos eco también de las buenas noticias que proceden de Campagnolo y que nos hablan de su 'marcha atrás' en lo que a despidos se refiere. Tras llegar a un acuerdo con los trabajadores, la marca sigue adelante con la idea de recuperar su operatividad y su lugar en el mercado. Finalmente, repasamos la actualidad y las presentaciones de algunos de nuestros equipos más destacados, como el Caja Rural-Seguros RGA y sus bicicletas MMR, presentes en el próximo Tour de Francia, el renovado Buff-BH Team y el ya clásico Orbea Fox Factory Team. Este episodio cuenta con el patrocinio de Canyon y su renovada Spectral:ON, que vuelve en 2026 mejor que nunca. Llega con una nueva batería de 800 Wh con carcasa de aluminio, más robusta y segura, mantiene el formato mullet y monta el fiable motor Shimano EP801. Todo ello con una gran relación calidad-precio que arranca en 3.999 €, demostrando que la e-MTB de alto nivel puede ser accesible. Descubre la renovada Canyon Spectral:ON a través de este enlace: https://www.canyon.com/es-es/bicicletas-electricas/mountain-bike-electrica/spectral-on/#section-product-grid Más referencias: Vittoria se suma al 32'' para XC y gravel: https://www.mtbpro.es/actualidad/vittoria-se-suma-tambien-las-ruedas-de-32-para-xc-y-gravel Campagnolo evita los despidos: https://www.maillotmag.com/actualidad/campagnolo-evita-los-despidos-y-sigue-trabajando-en-nuevos-lanzamientos Trek Charter+: https://www.maillotmag.com/actualidad/nueva-trek-charter-de-la-ciudad-los-caminos-con-una-sola-e-bike Caja Rural-Seguros RGA y MMR, al Tour 2026: https://www.maillotmag.com/actualidad/caja-rural-seguros-rga-y-mmr-estaran-en-el-tour-2026 Buff-BH Team, nuevos aires: https://www.mtbpro.es/actualidad/buff-bh-team-nuevos-aires-para-una-estructura-historica-del-xcm Orbea Fox Factory Team 2026: https://www.mtbpro.es/actualidad/orbea-fox-factory-team-2026

What does the future hold for time attack racing in North America?In this Race Industry Week by EPARTRADE interview, Jason Dienhart, President & CEO of Global Time Attack (GTA) and Super Lap Battle (SLB), delivers a candid, in-depth look at where the sport stands today—and where it's headed in 2026.From record-chasing at Buttonwillow to tough economic decisions and a renewed West Coast focus, Dienhart breaks down the realities of running niche motorsport events while protecting the culture that makes time attack special.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello discuss with disgust the decline and fall of American public health and the rise of "only me" when highlighting completion of the US withdrawal from the WHO and possibility of making IPV and MMR optional vaccines, before Dr. Griffin then deep dives into recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, Europe losing its measles elimination status, first measles death in Mexico, almost 1000 measles cases in South Carolina, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, the effectiveness of this season's influenza vaccine, where to go for answers to your long COVID questions and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode US completes withdrawal from World Health Organization (AP News) Rejecting Decades of Science, Vaccine Panel Chair Says Polio and Other Shots Should Be Optional (NY Times) A Frightening Interview (Beyond the Noise) Unexplained Pauses in Centers for Disease Control and Prevention Surveillance: Erosion of the Public Evidence Base for Health Policy (Annals of Internal Medicine) Wastewater for measles (WasterWater Scan) UK among 6 European countries losing measles elimination status (Dougall MD: DG Alerts) European Regional Verification Commission for Measles and Rubella Elimination (RVC) (WHO: Europe) Measles Outbreak Associated with an Infectious Traveler — Colorado, May–June 2025 (CDC: MMWR) South Carolina measles cases hit 789, surpassing Texas' 2025 outbreak total (Reuters) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) States across the country report first measles cases of year(CIDRAP) First measles death confirmed in Mexico in 2026 (Mexico News) Influenza: Waste water scan for 11  pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) Influenza Vaccine Effectiveness Among Children With and Without Underlying Conditions(Pediatrics) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Effectiveness and Durability of the BNT162b2 KP.2 vaccine against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults (OFID) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Association of Nirmatrelvir-ritonavir with intubation or mortality risks in severe COVID-19 patients (BMC Infectious Diseases) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1292 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

This week, we visit Marquette Michigan, a gem no matter the season. This fun town nestled on the shores of Lake Superior is home to Northern Michigan University and really knows how to embrace winter with a flurry of activities and festivals.We kick off the show with Susan Estler from Travel Marquette who gives us an overview of winter in MQT, and then quickly gets down to business with what we love the most, where to eat. You need to warm up at some point, right? And Marquette has an incredible restaurant scene to check out, from funky dive bars with great burgers (yes, we are looking at you Pat's Bar) to hip spots like The Delft Bistro, where you'll feel like you might be in a slightly larger city. Of course, we'll gush on and on about one of our favorites, and a must stop when in town, delicious Lagniappe, which is yes, located in a basement downtown. First and foremost, you don't want to miss the very popular (and fun!) Winterfest and Rail Jam which is happening January 31 to February 1, 2026. Billed as a "marathon of mountain culture", this weekend will feature ski races, live music, and a freesyle rail jam. A highlight is the Torchlight Parade happening Saturday night, please be sure to register at the front desk so you can get your glow on. Also, don't miss FRESH oysters apres ski at the famous T-Bar, you probably won't be finding those anywhere else in the Yoop this weekend. Sunday, enjoy more skiing and racing.Orignally opened in 1957 as Cliff's Ridge, Marquette Mountain Resort is beloved by both locals and visiting tourists alike. In winter, enjoy skiing and snowboarding via three chair lifts and a rope tow. In the warmer months, bring your mountain bike and explore the trails, or just strap on your hiking boots. Anyway you experience MMR, you are sure to have a great time. https://www.marquettemountain.com/Next, Jason Rolling, Race Director for the Noqueamon Ski Marathon, joins us to explain cross country ski racing to us, since there are several kinds of races you can paricipate in.  We found this extra helpful, because now we'll sound like we know what is going on during the Winter Olympics. Thank you Jason! Honestly, this race sounds like it's quite the experience. Jason also shares how important community support is for this race, from the volunteers, to local landowners granting permission for racers to cruise through their private land for the race. Just another reason to love our Yoopers. And, lookin ahead, the 2027 Noquemanon Ski Marathon will be held January 22nd-23rd, so you best start your training now.Finally, we meet Todd Poquette, Director of Adventure forthe Polar Roll, which is the largest fat tire bike race in Michigan, and part of the Great Lakes Fat Tire Series. There are three different races you can participate in on February 21, and we'll just leave you with the race's tag line...."it gets worse, before it gets better". Sounds like this one is for those with experience on the fat tire, we will be at the mass start, which sounds like it might be a little bit wild and right up our alley.We love Marquette, and hope that you do too. If so, be sure to check out the Respect Marquette pledge, and let's keep it amazing for all of us.

Marquette Mountain offers four season's of fun, through sun, and in the winter, tons and tons of snow. We talk with Kaet Johnson, the resort's general manager, about all there is to do and experience when you are here. First and foremost, you don't want to miss the very popular (and fun!) Winterfest and Rail Jam which is happening January 31 to February 1, 2026. Billed as a "marathon of mountain culture", this weekend will feature ski races, live music, and a freesyle rail jam. A highlight is the Torchlight Parade happening Saturday night, please be sure to register at the front desk so you can get your glow on. Also, don't miss FRESH oysters apres ski at the famous T-Bar, you probably won't be finding those anywhere else in the Yoop this weekend. Sunday, enjoy more skiing and racing.Orignally opened in 1957 as Cliff's Ridge, Marquette Mountain Resort is beloved by both locals and visiting tourists alike. In winter, enjoy skiing and snowboarding via three chair lifts and a rope tow. In the warmer months, bring your mountain bike and explore the trails, or just strap on your hiking boots. Anyway you experience MMR, you are sure to have a great time. https://www.marquettemountain.com/Find all the information you need to plan an amazing trip to the Marquette region at Travel Marquette.

The Study Cardiology Willfully Ignored for Over Two Decades Written by Sayer Ji on January 27, 2026. Posted in Current News' https://principia-scientific.com/the-study-cardiology-willfully-ignored-for-over-two-decades/     Authored by Lois Lamerato et al. from Henry Ford Health System study by Lois Lamerato et al  of data from Michigan's integrated healthcare system in Michigan to compare chronic health outcomes in vaccinated versus unvaccinated children. Vaccination exposure was defined as receiving at least one vaccine Vaccinated children had a 2.5 higher adjusted hazard ratio for any chronic condition Specific increcases include asthma, autoimmune disease, atopic disease, eczema, and neurodevelopmental disorders. The 10-year probability of being free from chronic conditions was 83% in unvaccinated vs. 43% in vaccinated. No conditions were higher in unvaccinated.   Study by AR Mawson et al – J Translational Science Survey-based study compared homeschooling children who were vaccinated versus unvaccinated. Higher rates of neurodevelopmental disorders, asthma, and allergies among vaccinated children Vaccinated children had fewer vaccine-preventable infections.   Study by BS Hooker et al – SAGE Open Medicine Retrospective analysis of health outcomes between vaccinated and unvaccinated children. Higher rates of asthma, developmental delays and ear infections in vaccinated children.   Study by NZ Miller – J Translational Science A follow-up analysis to adjust for additional covariates such as breastfeeding and cesarean birth. Reported increased odds of certain chronic conditions among vaccinated children. This is not very convincing study if I am to be honest   Study by AR Mawson & BS Hooker – Frontiers of Public Health Analyzed pediatric billing data and reported increased office visits and diagnoses among vaccinated children. Reported igher rates of neurodevelopmental disorders, asthma, and allergies in vaccinated children However, the journal retracted this article on the grounds it did not disclose conflicts of interest   University of Hong Kong -- This one I know from memory – don't know the journal Double blind placebo study comparing flu vaccinated vesus saline placebo vaccinated Followed for 9 months Vaccinated – almost 4-fold increase in getting other non-flu respiratory infections compared to unvaccinated Only slight increase in flu cases among unvaccinated compared to vaccinated   DeStefano et al -- J Translational Neurdegeneration Study analyzed children in metropolitan Atlanta to examine a link between the age of first MMR vaccine receipt and autism diagnosis. Reports that earlier MMR vaccination increased autism risk in specific subgroups, compared to to later-vaccinated children.   J Lyons-Weiler – Intl J Environmental Research and Public Health Unvaccinated children reportedly had fewer chronic illnesses but more vaccine-preventable infections.   Roma Schmitz et al -  Deutsch Arztebl Intl (German journal) – early study in 2011 Large survey to assess whether vaccination status affects infectious and atopic diseases. Unvaccinated had higher vaccine-preventable diseases (e.g., pertussis, measles) but lower atopic diseases There were fewer median infections in unvaccinated young   P Aaby et al – series of studies between 1995-2016 – BMJ, Vaccine, J Tropical Medicine Some vaccines (especially DTP) associated with higher all cause mortality in low income settings compared to those who did not receive DTP  

John Schoen, Senior Clinical Manager of Evidence-Based Medicine and Drug Information in Vizient's Center for Pharmacy Practice Excellence and Vizient's vaccine subject matter expert, joins host Stacy Lauderdale to discuss key updates to the CDC's childhood Immunization schedule and what they mean for practice.   Guest speaker:     John Schoen, PharmD, BCPS   Senior Clinical Manager of Evidence-Based Medicine and Drug Information    Vizient Center for Pharmacy Practice Excellence     Host:   Stacy Lauderdale, PharmD, BCPS   Associate Vice President  Vizient Center for Pharmacy Practice Excellence   Verified Rx Host    00:00 — Introduction Announcer welcomes listeners to Verified Rx, produced by the Vizient Center for Pharmacy Practice Excellence. 00:14 — Episode Overview Host Stacy Lauderdale introduces the topic: updates to the CDC's U.S. Childhood Immunization Schedule, revised January 20, 2026. Goal of the episode: explain what changed, what didn't, and what it means in practice for providers, pharmacists, and families. Guest: John Schoen, Senior Clinical Manager of Evidence-Based Medicine and Drug Information at Vizient and vaccine subject matter expert. 01:16 — What Changed in the CDC Immunization Schedule CDC reorganized the schedule into three recommendation categories. Vaccines were reclassified, not removed. Number of diseases covered under “routine” recommendations decreased from 17 to 11 due to recategorization. 01:50 — Stated Rationale Behind the Changes Rationale provided in executive summary of scientific assessment. The supporting scientific assessment is available online and referenced for transparency (link in resources below). 03:19 — Were Any Vaccines Removed? No vaccines were removed from the CDC schedule. Some vaccines were shifted into different recommendation categories. 03:40 — Category 1: Routine Childhood Vaccinations Vaccines still routinely recommended for all children include: MMR (measles, mumps, rubella) Polio Tdap / DTaP Hib (Haemophilus influenzae type B) Pneumococcal HPV Varicella (chickenpox) 04:27 — Category 2: Vaccines for High-Risk Populations Vaccines recommended for children who meet specific high-risk criteria: RSV monoclonal antibodies (mAb) Hepatitis A Hepatitis B Quadrivalent meningococcal Meningococcal group B Dengue 05:19 — What Changed vs. Stayed the Same Hepatitis A, Hepatitis B, and quadrivalent meningococcal moved from routine to high-risk RSV mAb recommendations are effectively unchanged, as high-risk infants are defined as those born to mothers who did not receive the maternal RSV vaccine. Dengue remains risk-based. Meningococcal group B remains a mix of risk-based and shared clinical decision-making. 06:31 — Category 3: Shared Clinical Decision Making (SCDM) Defined by ACIP as an individualized decision made jointly by provider and parent/guardian. Allows vaccination when risk-based criteria are not met but benefit is still considered. 06:52 — Vaccines Under SCDM Vaccines now include: Influenza COVID-19 Rotavirus Hepatitis A Hepatitis B Quadrivalent meningococcal Meningococcal group B 08:05 — What's New in SCDM Influenza and rotavirus moved from routine to SCDM. Hepatitis A, hepatitis B, and quadrivalent meningococcal also shifted. COVID-19 moved to SCDM in September 2025 for individuals ≥6 months. 08:28 — Insurance Coverage Implications No expected changes in coverage. Vaccines recommended by CDC as of December 31, 2025 remain: Covered without cost-sharing under Affordable Care Act (ACA) plans. Covered by Medicaid, Children's Health Insurance Program (CHIP), and Vaccines for Children (VFC) program. 09:14 — Impact on Pharmacy Vaccine Access Pharmacists are considered healthcare providers under CDC SCDM definitions. Authority to administer vaccines primarily determined by state laws. Standing orders, protocols, and collaborative practice agreements may need to be updated, as applicable, to address language related to ‘routine' immunizations for children. 10:27 — Recommendations for Providers & Organizations For providers: Become familiar with schedule changes. Be prepared for patient and parent education. Recognize differences between CDC and other professional guidelines. For organizations: Review EHR documentation and order sets. Consult local state regulations to ensure compliance with vaccine administration practices. Review standing orders/protocols and collaborative practice agreements to determine if revisions are needed. Monitor vaccine utilization and adjust inventory accordingly. 11:24 — Resources & Closing Additional CDC and Vizient resources will be linked in the show notes. Announcer closes with subscription and feedback reminder. Links | Resources:    Additional resources HHS press release on changes to childhood immunizations schedule Assessment of US childhood and adolescent immunization schedule HHS fact sheet: CDC childhood immunization schedule Revised CDC child and adolescent immunization schedule ACIP shared clinical decision-making recommendations   Vizient resource Minute Market Insight   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed  

ESMO Episode 6 is here! The longest award ceremony in the world continues. This episode covers colorectal cancer, a cancer stream that has relied heavily on the same three drugs for the past twenty-five years.We cover the golden pinnacle of real-world use cases for CTDNA, neoadjuvant immunotherapy in those with proficient MMR colorectal cancer, whether Zanzalimab helps in refractory colorectal cancer, and much more.Studies:BREAKWATERNEOADJUVANT IMMUNOTHERAPY (pMMR)STELLAR-303CHECKMATE 8HWFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Lindsey sits down with pediatrician Dr. Joel Warsh a.k.a. Dr. Gator, author of Between a Shot and a Hard Place, for the conversation every mom needs to hear. Get an honest look at vaccine safety, parental autonomy, and trusting your intuition in a world of conflicting advice. Ahead, Lindsey + Dr. Gator dive into the chronic illness epidemic—exploring everything from the long-term effects of vaccines to the rise in allergies, autism, and autoimmune conditions in kids today. You'll learn why asking questions isn't “woo-woo”—it's essential to make informed choices.  If you've ever felt judged for going “off schedule” or considered an alternative vaccine approach, this episode brings nuance, compassion, and real data. From toxic ingredients to finding the right doctor, don't miss this must-listen for parents who care about wellness, safety, and sovereignty. We also talk about: The real reasons vaccine schedules have skyrocketed in recent decades What ingredients in vaccines could mean for your child's health Why most doctors won't see families who want alternative vaccine schedules—and what to do about it Debunking the “safe and effective” narrative + what parents actually want to know The myth vs. reality of vaccine injury reporting (VAERS) + what gets missed Pros + cons of delaying or spacing out vaccines—and how to weigh the risks The truth about Hepatitis B at birth, polio, and why some shots might be less urgent than you think Autism, MMR, and the data gaps that you need to hear about Finding “your people” as a parent when conversations around vaccines feel taboo Empowerment tips on trusting your gut, advocating for your child, and demanding better research Resources: Instagram: @drjoelgator X: @drjoelgator Book: www.theshotbook.com Order our book, Almost 30: A Definitive Guide To A Life You Love For The Next Decade and Beyond, here: https://bit.ly/Almost30Book.  Sponsors: Fatty15 | Get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/ALMOST30 and use code ALMOST30 at checkout.  Ka'Chava | Go to kachava.com and use code ALMOST30 for 15% off your next order. Hero Bread | Hero Bread is offering 10% off your order. Go to hero.co and use code ALMOST30 at checkout. Revolve | Shop at REVOLVE.com/ALMOST30 and use code ALMOST30 for 15% off your first order. #REVOLVEpartner BetterHelp | This episode is brought to you by BetterHelp. Give online therapy a try at betterhelp.com/almost30 and get on your way to being your best self with 10% off your first month. Chime | It just takes a few minutes to sign up. Head to Chime.com/ALMOST30. Paleovalley | Head to paleovalley.com/almost30 for 15% off your order! Our Place | Visit fromourplace.com/ALMOST30 and use code ALMOST30 for 10% off sitewide.  To advertise on this podcast please email: partnerships@almost30.com. Learn More: https://almost30.com/about https://almost30.com/morningmicrodose https://almost30.com/book Join our community: https://facebook.com/Almost30podcast/groups https://instagram.com/almost30podcast https://tiktok.com/@almost30podcast https://youtube.com/Almost30Podcast Podcast disclaimer can be found by visiting: almost30.com/disclaimer.  Almost 30 is edited by Garett Symes and Isabella Vaccaro. Learn more about your ad choices. Visit megaphone.fm/adchoices

Automatic Script Execution In Visual Studio Code Visual Studio Code will read configuration files within the source code that may lead to code execution. https://isc.sans.edu/diary/Automatic%20Script%20Execution%20In%20Visual%20Studio%20Code/32644 Cisco Unified Communications Products Remote Code Execution Vulnerability A vulnerability in Cisco Unified Communications Manager (Unified CM), Cisco Unified Communications Manager Session Management Edition (Unified CM SME), Cisco Unified Communications Manager IM & Presence Service (Unified CM IM&P), Cisco Unity Connection, and Cisco Webex Calling Dedicated Instance could allow an unauthenticated, remote attacker to execute arbitrary commands on the underlying operating system of an affected device. https://sec.cloudapps.cisco.com/security/center/content/CiscoSecurityAdvisory/cisco-sa-voice-rce-mORhqY4b Zoom Vulnerability A Command Injection vulnerability in Zoom Node Multimedia Routers (MMRs) before version 5.2.1716.0 may allow a meeting participant to execute remote code on the MMR via network access. https://www.zoom.com/en/trust/security-bulletin/zsb-26001/ Possible new SSO Exploit (CVE-2025-59718) on 7.4.9 https://www.reddit.com/r/fortinet/comments/1qibdcb/possible_new_sso_exploit_cve202559718_on_749/ SANS SOC Survey The 2026 SOC Survey is open, and we need your input to create a meaningful report. Please share your experience so we can advocate for what actually works in the trenches. https://survey.sans.org/jfe/form/SV_3ViqWZgWnfQAzkO?is=socsurveystormcenter

A large U.S. cohort study found that children who were late for routine 2- or 4-month immunizations were six to seven times more likely to miss MMR vaccination entirely by age two, highlighting early delays as a strong predictor of future vaccine refusal amid rising measles cases. A long-term study of more than 27,000 women showed that very high lipoprotein(a) levels were associated with substantially increased cardiovascular risk over 30 years, supporting targeted one-time screening. Finally, Medicare data revealed that one in four older adults with dementia received CNS-active medications, often without clear indications, underscoring opportunities to reduce inappropriate prescribing.

Kyle welcomes Dr. Andrew Wakefield, a controversial figure known for his claims linking the MMR vaccine to autism. Wakefield shares his journey from a traditional medical background to becoming a prominent critic of vaccines. The podcast covers the initial study published in The Lancet, its subsequent backlash, and Wakefield's journey through public and professional challenges. Wakefield discusses his transition to filmmaking as a means to spread his message, highlighting his documentary 'Vaxxed' and other key works. The conversation delves into the impact of vaccines on public health, the introduction and potential risks of mRNA vaccines, and broader issues surrounding vaccine policies and public trust. Highlighted are the testimonies of parents with vaccine-injured children, the legal and scientific battles against the mainstream medical community, and the importance of public awareness. The podcast also explores alternative treatments for vaccine-related injuries, emphasizing gut health and the potential benefits of cannabinoids. Dr. Wakefield expresses hope for more informed public health policies and discusses his plans for future projects, including a film addressing the long-term impacts on children left behind by vaccination policies.   Connect with Andy here: Website - Wakefield Media Group Instagram   From Kyle: The Community is coming! Click here to learn more Full Temple Reset is back with Erick Godsey, Click here to learn more   Our Sponsors: Let's level up your nicotine routine with Lucy. Go to Lucy.co/KKP and use promo code (KKP) to get 20% off your first order. Lucy offers FREE SHIPPING and has a 30-day refund policy if you change your mind. These are the b3 bands I was talking about. They are amazing, I highly recommend incorporating them into your movement practice. Go to tonum.com/KKP, use the code KKP, and get 10% off your first order of Nouro.   Connect with Kyle: I'm back on Instagram, come say hey @kylekingsbu Twitter: @kingsbu Our Farm Initiative: @gardenersofeden.earth Odysee: odysee.com/@KyleKingsburypod Youtube: https://www.youtube.com/@Kyle-Kingsbury Kyle's Website: www.kingsbu.com - Gardeners of Eden site If you enjoyed this podcast, please subscribe & leave a 5-star review with your thoughts!

A focused conversation on how MMR partners and athletics marketing teams can align, communicate, and collaborate to reach shared goals. From sales season launch to mid-year check-ins, this episode highlights practical strategies, common challenges, and ways both sides can work together to maximize revenue, elevate the fan experience, and strengthen the athletics brand.

Under Health Secretary RFK Jr's guidance, the CDC has made changes to recommendations for the childhood vaccine schedule. Jessica Malaty Rivera, infectious disease epidemiologist and member of the group Defend Public Health, explains what the changes are and why they are such a big deal for public health.

In "Flu Takes Charge" Dr. Osterholm and Chris Dall give us an update on the emerging flu season, Dr. Osterholm covers a new poll that shows fewer Americans are willing to recommend the MMR vaccine, and we'll hear about the Vaccine Integrity Project's latest video.Resources for vaccine and public health advocacy: Voices for Vaccines Families Fighting Flu Vaccinate Your Family Shot@Life Medical Reserve Corps Learn more about the Vaccine Integrity Project MORE EPISODES       SUPPORT THIS PODCAST

We are away for Christmas, so this is a repeat of a previous episode. In September, President Trump and the U.S. Health Secretary Robert F. Kennedy Jr. held a press conference in which they made extraordinary new claims about autism. They suggested a potential link between the use of Tylenol during pregnancy and the development of autism. They also advocated spacing out childhood vaccinations. The two men's interest in the link between vaccines and autism goes back decades but these claims did not originate in the US. They trace back to the UK in 1998, when disgraced former doctor Andrew Wakefield first published his now-debunked theory linking MMR vaccines to autism cases in children. The science journalist Adam Rutherford explains to the Global Story how the Wakefield vaccine conspiracy became the biggest medical disinformation disaster in recent history, and how these ideas found fertile ground in the Trump administration. Producers: Viv Jones, Valerio Esposito Executive producer: Annie Brown, James Shield Mix: Travis Evans Senior news editor: China Collins Photo: President Trump & Robert F. Kennedy Jr. Kevin Lamarque/Reuters

How Conventional Medicine Is Ruining Our Kids | Dr. Larry PalevskyTurn online alignment into an offline community — join us at TheWayFwrd.com to connect with like-minded people near you.We're watching an entire generation of children get sicker, and the medical system still won't admit it's out of answers. Parents see it. Practitioners see it. And the gap between real-world patterns and the official explanations around childhood illness keeps widening.In this episode, Dr. Larry Palevsky breaks down the observations that pushed him to question the pediatric model from within. Standard protocols weren't helping. Some interventions were making symptoms worse. And the infection-based framework he was trained to follow simply didn't explain the chronic inflammation, neurodevelopmental issues, or immune dysregulation showing up in real kids.Looking for clarity, he stepped outside the conventional lane—into nutrition, Chinese medicine, chiropractic, reiki, herbology, and other holistic approaches that offered a fuller picture of children's health. That search opened deeper questions about vaccine ingredients, aluminum adjuvants, immune overload, environmental toxicity, and whether our definition of “infection” actually matches what's happening inside children's bodies.This conversation is for anyone who already knows the system is breaking kids—and wants the language, context, and coherence to understand why, and what truly supports long-term health.You'll Learn:[00:00:00] Introduction[00:06:23] The lost art of Clinical Medicine[00:07:38] The emergency room revelation about ear infections and antibiotics[00:12:21] Discovering the concept of "the body has the innate capacity to heal"[00:17:09] Using reiki in the delivery room to save babies[00:23:24] The pivotal moment a mother asked about mercury in vaccines[00:26:42] The premature baby saved by fish oil[00:33:14] Why Dr. Larry stopped vaccinating and started educating[00:42:18] The troubling science of aluminum adjuvants in vaccines[01:03:08] Three brain regions where nanoparticles travel[01:06:29] What sorbitol in MMR might actually be doing[01:18:21] Why vaccines are "safe and effective" is the wrong debate[01:24:10] The real contagion theory no one talks about[01:34:07] Acute illness is rarely an infection[01:48:42] The 15-year-old diagnosed with autism who actually had addiction[01:41:59] The autism debate, diagnostic labels, and the dozen causes of brain injury in children[02:04:26] The parenting advice that sounds cruel but builds resilience[02:08:40] What "making children well again" actually requires [02:22:15] Symptoms are just the body doing its job[02:16:53] The two-part vision: reforming pediatrics and reclaiming allopathic medicineResources Mentioned:Danish Study on 1.2 Million Children Settles the Vaccine-Autism Debate | ArticleCan You Catch A Cold? By Daniel Roytas | BookFind more from Dr. Larry Palevsky:Dr. Palevsky | WebsiteDr. Palevsky | InstagramFind more from Alec:Alec Zeck | InstagramAlec Zeck | XThe Way Forward | InstagramThe Way Forward is Sponsored By:Designed for deep focus and well-being. 100% blue light and flicker free. For $50 off your Daylight Computer, use discount code: TWF50New Biology Clinic: Redefine Health from the Ground UpExperience tailored terrain-based health services with consults, livestreams, movement classes, and more. Visit www.NewBiologyClinic.com and use code TheWayForward for $50 off activation. Members get the $150 fee waived

Brent Smith and Zach Myers of Shinedown visited the WMMR studios to chat with Pierre Robert. Zach reveals he thinks Pierre has the most soothing voice, so Pierre starts reading him a bedtime story. They also discuss the new Amaryllis record and how MMR is "Keeping rock alive". See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease. Episode Highlights: • Overview of recent advancements in the treatment of resectable disease, including the approval of Durvalumab in perioperative settings. • Discussion on the importance of biomarker testing, including HER2, PD-L1, MMR, and Claudin 18.2, in determining treatment options. • Insights into frontline treatment strategies for HER2-positive patients, including the role of trastuzumab and the addition of pembrolizumab based on PD-L1 status. • The significance of retesting HER2 expression upon disease progression and the implications for treatment decisions. • Exploration of emerging therapies like TDXd and Zanidatamab, and their potential impact on the treatment landscape. • Considerations for managing side effects and the importance of treatment sequencing in palliative care. Join us for an informative discussion that aims to keep community oncologists up to date in this ever-evolving field of cancer treatment. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes covering treatment algorithms, FDA approvals, and conference highlights! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/biomarker-testing-in-her2-gea-diagnosis-and-treatment-implications    #HER2GastricCancer #GastricCancer #BiomarkerTesting #OncologyBrothers #GIOncology #CME

Send us a textA father that gives birth, a horse that says “no,” and an ER doctor who wants to keep you out of the hospital—this episode brings science and everyday choices into sharp focus. We start with a mind-bending dive into seahorses, where males carry the pregnancy and build a placenta-like environment from skin. New research shows familiar pregnancy genes at work inside the brood pouch, but with an unexpected hormonal switch: androgens, not estrogens, drive gestation. It's evolution repurposing its toolkit—and a powerful reminder that sex roles in nature are more flexible than we think.From there, we move into animal-assisted therapy and the role of consent in touch. A new study comparing dogs and horses found that forced interactions with horses raised heart rate and lowered HRV, signaling more stress, while choice calmed people down. Dogs showed no significant difference between conditions, suggesting human perception and species-specific behavior shape outcomes. If you run therapy programs, the insight is simple and humane: build animal choice into sessions, especially with horses, and track long-term welfare alongside human benefits.Then ER physician Dr. Shazma Mithani joins us to turn insight into prevention. We talk helmets for anything on wheels or snow, why e‑scooters drive more severe injuries per use than bikes, and how regular checkups and screening prevent emergencies before they start. We break down wildfire smoke—how particulates inflame lungs and harm the heart and brain—plus when to wear a well-fitted N95 outside and how to upgrade home air with MERV 11–13 filters or HEPA purifiers. Finally, we tackle measles: an airborne virus that lingers for hours, demands 95% vaccination for herd immunity, and is best stopped with two doses of MMR. Unsure where to get trusted answers? Talk to your doctor, pharmacist, or public health nurse, and lean on credible sources rather than influencers.If this helped you think differently about biology, safety, or public health, tap follow, share it with a friend, and leave a review with your biggest takeaway—we'll feature our favorites next week.Dr. Shazma Mithani's links:Her websiteHer PodcastInstagramOur links!Support the showFor Science, Empathy, and Cuteness!Being Kind is a Superpower. All our social links are here!

Could compulsory childhood immunisation - like Australia's No Jab/ No Play policy - help boost New Zealand's low vaccination coverage? Since the current measles outbreak began 50 days ago, MMR measles mumps and rubella vaccinations have surged 300 percent to more than 60-thousand. Ruth Hill reports.

Send Zorba a message!Zorba's thoughts on recent efforts by the US Centers for Disease Control and Prevention (CDC) and Health and Human Services Secretary Robert F. Kennedy Jr. to link autism to common immunizations.Zorba mentions a Dutch study that found no link between the MMR vaccine and autism. Here is that study:https://pmc.ncbi.nlm.nih.gov/articles/PMC1124634/(Recorded Nov 30 2025)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

Send Zorba a message!Zorba's thoughts on recent efforts by the US Centers for Disease Control and Prevention (CDC) and Health and Human Services Secretary Robert F. Kennedy Jr. to link autism to common immunizations.Zorba mentions a Dutch study that found no link between the MMR vaccine and autism. Here is that study:https://pmc.ncbi.nlm.nih.gov/articles/PMC1124634/(Recorded Nov 30 2025)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

Howie and Harlan are joined by Peter Hotez, a vaccine expert and an outspoken opponent of health misinformation, to discuss vaccine skepticism and the forces—from wellness influencers to HHS secretary Robert F. Kennedy Jr.—that amplify it. Harlan reports on research reinforcing the link between social media and mental illness; Howie highlights two potential areas of common ground with the administration's health policy.  Show notes: Social Media and Mental Health "Social Media Detox and Youth Mental Health" "Study Finds Mental Health Benefit to One-Week Social Media Break" Peter Hotez Peter Hotez: Science Under Siege: How to Fight the Five Most Powerful Forces That Threaten Our World Peter Hotez: Vaccines Did Not Cause Rachel's Autism: My Journey as a Vaccine Scientist, Pediatrician, and Autism Dad "Scientist pressured by Musk and Rogan to debate RFK Jr over anti-vaccine misinformation says he won't be part of 'Jerry Springer' show" Peter Hotez on X "Kennedy Says He Told C.D.C. to Change Website's Language on Autism and Vaccines" "Wakefield's article linking MMR vaccine and autism was fraudulent" "Four vaccine myths and where they came from" "Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism" "Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure" "Data investigation: Childhood vaccination rates are backsliding across the U.S." "South Carolina's Measles Outbreak Shows Chilling Effect of Vaccine Misinformation" "How a measles outbreak overwhelmed a small West Texas town" "How polio came back to New York for the first time in decades, silently spread and left a patient paralyzed" "Third infant in Kentucky dies of whooping cough as national cases stay high for second year in a row" "Kennedy minimizes measles outbreak in wake of Texas death" "RFK Jr. claims 'leaky' measles vaccine wanes over time. Scientists say he's wrong." "RFK Jr. claims measles can be treated with vitamin A, linked to poor diet. Here's what science says" "The Surprise Ending to the Trump-Mamdani Buddy Movie Has Heads Spinning" "Operation Warp Speed was one of Trump's biggest achievements. Then came RFK Jr. and vaccine skeptics" Health & Veritas Episode 196: The Cost Curve, Flu, and Other News "Weaponized Health Communication: Twitter Bots and Russian Trolls Amplify the Vaccine Debate" ACA Subsidies "Trump was going to roll out a health care plan. Then Republicans weighed in." "Trump Is Considering a Push to Extend Obamacare Subsidies" Site-Neutral Payment "The Trump Administration Moves Forward with Medicare Site-Neutral Payment Reform" "Five Things to Know About Medicare Site-Neutral Payment Reforms" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Measles cases at Wasatch High rise to 8, Park City School District urges MMR vaccination amid Wasatch County measles outbreak, Christian Center of Park City Executive Director Steve Richardson and Rob Paul on Thanksgiving food drive, Republic Services' Ashlee Cawley on winter trash pickup, plans for new recycling bins in Summit County, Judge dismisses fraud allegation in DeBoer wrongful death lawsuit, Jeremiah Lafranca, Executive Director of the American Red Cross Greater Salt Lake Chapter on holiday cooking and general safety, SLC airport braces for 120K travelers over Thanksgiving holiday, No Name Saloon celebrates 25 years with annual Thanksgiving ‘Freebird' dinner, Park City seeks local input on Gordo property environmental plan and UTA ski bus starts service to Cottonwood canyons, Ogden, Provo.

In the latest episode of our podcast, we explore the complexities of neurodivergence, we aim to shed light on how various conditions, such as autism, ADHD, and anxiety, affect individuals differently. The conversation is sparked by a recent update from the CDC regarding vaccines and their potential link to autism a topic that has stirred intense debate among parents, health professionals, and the general public. Tune into the discussion.

In a jaw-dropping call during the second hour of Episode 1106, a listener named Mark from New Orleans dropped what Clay called a “mind-blown” theory on the ongoing crisis of the feminization of American men and the explosion of hyper-masculine women and gender confusion in kids. Mark pointed to a little-discussed ingredient in many childhood vaccines since the late 1980s: aborted fetal cell lines (specifically MRC-5 and WI-38, derived from elective abortions in the 1960s) that are still used in the production of vaccines like MMR, varicella (chickenpox), hepatitis A, and others on the CDC schedule.   His argument: when you inject young children—boys and girls—with genetic material from the opposite sex (male fetal DNA into girls, female fetal DNA into boys), the body can incorporate that foreign DNA (a process called microchimerism). Over time and with multiple shots, this persistent foreign DNA may trigger immune confusion and hormonal disruption, essentially “reprogramming” sexual development. Mark tied it directly to the dramatic rise in boys exhibiting low muscle mass, high estrogen traits, and gender dysphoria, and girls becoming increasingly tomboyish or identifying as trans. He stressed that the vaccine schedule ballooned after 1989 (when liability protection was granted and fetal cell lines became standard), coinciding almost perfectly with the generational drop in testosterone and surge in gender-related mental health issues.   Clay, visibly stunned on air, connected it to the old saying that a woman who sleeps with multiple men retains tiny amounts of each man's DNA forever (microchimerism again), then extended the logic: “If a little bit of a man's DNA can live in a woman forever and affect her, what the hell is aborted fetal DNA from the opposite sex doing when we shoot it straight into little kids over and over?” The call ended with Clay's red-flag alarms going off, declaring he'd never considered that angle before but now couldn't unsee it, calling it one of the most disturbing yet plausible explanations he'd heard for why American boys are turning into “soy boys” and girls are being pushed toward masculinization at younger and younger ages. Absolute show-stopper moment.  

AlabamaAL Republicans says facts will prevail in CO lawsuit over decision to move US Space Command to HuntsvilleSen. Tuberville says corrupt marxist judges and leaders will destroy US citiesAPI releases in depth report on Alabama Education Association ties to NEADonald Watkins Jr. withdraws from consideration for Montgomery positionTwo state lawmakers are appointed as vice chairman to senate committeesBirmingham allocates $1M in emergency food relief when SNAP funding endsNationalPresident Trump makes deal with South Korea over gas, oil and shipbuildingTrump meets with Chinese president and both agree to trade truce for 1 yearFBI director fires lead agent in Arctic Frost operation led by Jack SmithFBI director reportedly had tense meeting with Joe Kent of counterterrorism center over docs that Kent got re: Charlie Kirk assassinationHHS secretary considering the breakup of the MMR vaccine for children

Autism isn't new, but our understanding of it has changed dramatically. It's now recognized as a broad neurodevelopmental spectrum that shapes how millions of people perceive, process, and interact with the world. In this episode, we explore what autism is AND isn't, from its earliest signs in infancy to its deep genetic roots, and why misinformation about it continues to spread. We speak with three remarkable experts leading the field in early detection, genetics, and public education: DR. AMI KLIN, PhD, Director of the Marcus Autism Center at Emory University and a pioneer in early autism research, whose work shows autism can be identified in babies as young as two months old. DR. JOSEPH BUXBAUM, PhD, Director of the Seaver Autism Center at Mount Sinai and a global leader in autism genetics, uncovering hundreds of genes linked to the condition. DR. ANDREA LOVE, immunologist, microbiologist, and founder of ImmunoLogic, known for her clear, evidence-based communication about vaccines, immunity, and autism myths. Together, we discuss: • What autism really is, and how the definitions have evolved • How it develops in infancy (and why early diagnosis can be so critical) • The powerful genetic evidence behind autism • The persistence of vaccine myths, and how misinformation spreads • How technology like eye-tracking can detect autism early • The rise of “profound autism” and what it means for families • The future of genetics-based treatments and therapy Whether you're autistic yourself, a parent navigating a new diagnosis, or simply seeking understanding, we're thrilled to share this extensive, in-depth episode with you. This is... Your Brain On Autism. SUPPORTED BY: the 2026 NEURO World Retreat. A 5-day journey through science, nature, and community, on the California coastline: https://www.neuroworldretreat.com/ ‘Your Brain On' is hosted by neurologists, scientists, and public health advocates Ayesha and Dean Sherzai. ‘Your Brain On... Autism' • SEASON 6 • EPISODE 1 LINKS Dr. Ami Klin at Emory University: https://ctsn.emory.edu/faculty/klin-ami.html Dr. Ami Klin at Marcus Autism Center: https://www.marcus.org/about-marcus-autism-center/meet-our-leadership/ami-klin  Dr. Joseph Buxbaum at Mount Sinai: https://profiles.icahn.mssm.edu/joseph-d-buxbaum  Dr. Andrea Love's website: https://www.immunologic.org/ Dr. Andrea Love on Instagram: https://www.instagram.com/dr.andrealove  REFERENCES Autism Spectrum Disorder: A Review. JAMA, 2023. https://jamanetwork.com/journals/jama/article-abstract/2800182  Is There a Bias Towards Males in the Diagnosis of Autism? A Systematic Review and Meta-Analysis. https://link.springer.com/article/10.1007/s11065-023-09630-2  Acetaminophen Use During Pregnancy and Children's Risk of Autism, ADHD, and Intellectual Disability. https://pubmed.ncbi.nlm.nih.gov/38592388/  Eye-Tracking–Based Measurement of Social Visual Engagement Compared With Expert Clinical Diagnosis of Autism. https://jamanetwork.com/journals/jama/fullarticle/2808996  Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. https://www.nature.com/articles/s41588-022-01104-0  Rare coding variation illuminates the allelic architecture, risk genes, cellular expression patterns, and phenotypic context of autism. https://www.medrxiv.org/content/10.1101/2021.12.20.21267194v1  Andrew Wakefield and the fabricated history of the alleged vaccine-autism link. https://geneticliteracyproject.org/2024/04/29/andrew-wakefield-and-the-fabricated-history-of-the-alleged-vaccine-autism-link/ VACCINES & AUTISM 1. Major Cohort Studies Hviid et al., 2019 – Annals of Internal Medicine A nationwide study of 657,461 Danish children found no increased risk of autism in vaccinated children compared to unvaccinated peers — even among those with risk factors such as a sibling with autism. Ann Intern Med. 2019;170(8):513–520 Madsen et al., 2002 – New England Journal of Medicine In 537,303 Danish children, researchers found no difference in autism rates between vaccinated and unvaccinated groups, and no relationship with age, timing, or date of vaccination. NEJM. 2002;347:1477–1482 Jain et al., 2015 – Journal of the American Medical Association (JAMA) A U.S. cohort of 95,727 children — including those with siblings with autism — showed no link between MMR vaccination and autism risk, even in genetically predisposed children. JAMA. 2015;313(15):1534–1540 Madsen et al., 2003 – JAMA A study of 467,450 Danish children found no relationship between thimerosal-containing vaccines and autism. JAMA. 2003;290(13):1763–1766 DeStefano et al., 2022 – Vaccine A retrospective cohort of over 500,000 U.S. children with ASD found no increase in adverse events or worsening of autism-related symptoms following vaccination. Vaccine. 2022;40(16):2391–2398 2. Population-Level Epidemiologic Evidence Taylor et al., 1999 – The Lancet One of the earliest large epidemiological studies found autism prevalence was the same in vaccinated and unvaccinated children, and the age of onset was unrelated to the timing of MMR vaccination. Read: Lancet. 1999;353(9169):2026–2029 Institute of Medicine (U.S.) Immunization Safety Review, 2011 A global review of studies from the U.S., Denmark, Sweden, and the U.K. concluded there is no causal relationship between vaccination status and autism, and no plausible biological mechanism linking vaccines (including thimerosal) to ASD. Read: National Academies Press / PubMed 20669467 3. Systematic Reviews and Meta-Analyses Taylor et al., 2014 – Vaccine A comprehensive meta-analysis of 10 studies including over 1.2 million children found no association between vaccination and autism or ASD. Vaccine. 2014;32(29):3623–3629 Maglione et al., 2014 – Pediatrics Review of 67 high-quality studies covering the full U.S. immunization schedule concluded that vaccines are safe, adverse events are rare, and there is no link to autism, type 1 diabetes, or other chronic conditions. Pediatrics. 2014;134(2):325–337 Parker et al., 2004 – Pediatrics Systematic review of 10 primary studies examining thimerosal exposure found no relationship between vaccines and ASD. Authors noted that studies showing an association were methodologically flawed or biased, while robust studies consistently showed safety. Pediatrics. 2004;113(6):1904–1910 Offit & Hackett, 2003 – Clinical Infectious Diseases Review of immunology and epidemiology concluded that claims that vaccines “overwhelm” or “damage” the immune system are not biologically plausible based on how the immune system actually functions. Clin Infect Dis. 2003;46(9):1450–1456

This week, primary care physicians Kate Rowland, Mark Ebell, and Henry Barry want to arm our primary care colleagues with the best evidence on whether acetaminophen causes autism, whether MMR causes autism, and whether leucovorin can treat autism. Gary then turns to a study of the value of continuity in primary care, and its association with better health outcomes.Links:Henry's essay on Ignaz Semelweis, handwashing, and postage stamps: https://thestampforum.boards.net/thread/13044/current-issue-volume-jul-2025 Essential Evidence Plus and POEMs: www.essentialevidenceplus.comAcetaminophen in pregnancy and autism: https://www.ncbi.nlm.nih.gov/pubmed/38592388 Leucovorin to treat autism: https://www.ncbi.nlm.nih.gov/pubmed/15781839, https://www.ncbi.nlm.nih.gov/pubmed/34834493 MMR and autism, Wakefield investigation: https://www.bmj.com/content/342/bmj.c5347MMR and autism, Madsen's Danish study: https://pubmed.ncbi.nlm.nih.gov/12421889/ Value of primary care continuity: https://www.ncbi.nlm.nih.gov/pubmed/40355250And do NOT eat roadkill. Definitely.

In "Bending Not Breaking," Dr. Osterholm and Chris Dall discuss recent layoffs and layoff reversals at the CDC, comments from the administration on the MMR vaccine, and the latest respiratory virus data. Dr. Osterholm also shares an update on pertussis cases and answers an ID Query about herd immunity. Resources for vaccine and public health advocacy: Voices for Vaccines Families Fighting Flu Vaccinate Your Family Shot@Life Medical Reserve Corps Learn more about the Vaccine Integrity Project MORE EPISODES       SUPPORT THIS PODCAST

About this episode: Since 1971, combination mumps, measles, and rubella vaccines have protected American children against life-threatening infection. Recent calls to split the MMR vaccines into three separate injections could unravel decades of progress. In this episode: William Moss details the history of MMR vaccines and the public health dangers posed by changing immunization recommendations without scientific justification to do so. Guests: Dr. William Moss, MPH, is an infectious disease specialist and the executive director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content: Acting CDC director calls for MMR vaccine to be broken up into three shots—STAT What to Know About MMR and MMRV Vaccines—Johns Hopkins Bloomberg School of Public Health The MMR vaccines has been combined for decades… and for good reason—@johnshopkinssph via Instagram Vaccines 101: Understanding the Vaccines on the Childhood Vaccination Schedule—Public Health On Call (March 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

On Monday President Trump and the U.S. Health Secretary Robert F. Kennedy Jr. held a press conference in which they made extraordinary new claims about autism. They suggested a potential link between the use of Tylenol during pregnancy and the development of autism. They also advocated spacing out childhood vaccinations. The two men's interest in the link between vaccines and autism goes back decades but these claims did not originate in the US. They trace back to the UK in 1998, when disgraced former doctor Andrew Wakefield first published his now-debunked theory linking MMR vaccines to autism cases in children. Today on the Global Story science journalist Adam Rutherford explains how the Wakefield vaccine conspiracy became the biggest medical disinformation disaster in recent history, and how these ideas found fertile ground in the Trump administration. Every weekday, this is The Global Story. The world is changing. Decisions made in the US and by the second Trump administration are accelerating that change. But they are also a symptom of it. With Asma Khalid in DC, Tristan Redman in London, and the backing of the BBC's international newsroom, The Global Story brings clarity to politics, business and foreign policy in a time of connection and disruption. For more episodes, just search 'The Global Story' wherever you get your BBC Podcasts.

Setting: President Trump held a press conference after attending Charlie Kirk’s funeral, teasing it as a “major announcement” on autism and public health. Main Claim: Trump and RFK Jr. asserted that acetaminophen (Tylenol) use during pregnancy may be associated with an increased risk of autism in children. Trump directly warned against taking Tylenol while pregnant, except in extreme cases of high fever. Autism Statistics (as presented by Trump): Historical rates cited: 1 in 20,000 → 1 in 10,000 → 1 in 31 overall today, and as high as 1 in 12 among boys in some regions (e.g., California). He described this increase as “artificial” and linked it to medication and vaccines. Specific Policy Steps Announced: FDA to issue warnings and update labeling for acetaminophen, cautioning its use during pregnancy. NIH, FDA, CDC, and CMS to coordinate a new effort investigating potential environmental, pharmaceutical, and vaccine links to autism. New grant funding (13 awards) through NIH’s Autism Data Science Initiatives. Other Health Proposals Trump Raised: Vaccines: suggested spacing them out, avoiding certain ingredients (mercury, aluminum), giving MMR separately, and delaying hepatitis B vaccination until age 12. Treatment: referenced new findings suggesting folate deficiency in children may contribute to autism, with therapies under research. RFK Jr.’s Role: He emphasized that past autism research was too focused on genetics and ignored environmental/toxic exposures. Supported Trump’s push to investigate acetaminophen, vaccines, and other potential causes. Announced NIH/FDA would pursue depoliticized research, new label warnings, and public education campaigns. Please Hit Subscribe to this podcast Right Now. Also Please Subscribe to the The Ben Ferguson Show Podcast and Verdict with Ted Cruz Wherever You get You're Podcasts. And don't forget to follow the show on Social Media so you never miss a moment! Thanks for Listening X: https://x.com/benfergusonshowYouTube: https://www.youtube.com/@VerdictwithTedCruzSee omnystudio.com/listener for privacy information.

Brooke Gladstone speaks with Paul Offit, the director of the Vaccine Education Center and a physician in the Division of Infectious Diseases at Children's Hospital of Philadelphia, about how the Secretary of Health and Human Services, Robert F. Kennedy Jr., purged the CDC's vaccine advisory committee members, the controversial figures Kennedy replaced them with, and what impact this will have on the future of vaccines and immunology in the US.  On the Media is supported by listeners like you. Support OTM by donating today (https://pledge.wnyc.org/support/otm). Follow our show on Instagram, Twitter and Facebook @onthemedia, and share your thoughts with us by emailing onthemedia@wnyc.org.

Today we discuss RFK Jr. the CDC, autism and trans activism. Kennedy revealed this week that in 2002, the CDC destroyed data that showed that children who got the MMR vaccine before 36 months of age had far higher rates of autism than did those who get the vaccine later in life. An HHS report will soon be released that ties Tylenol use during pregnancy to autism—what does this tell us about past public health advice, safety and risk? How can we all become better at pattern recognition? Florida Surgeon General Joe Ladapo is moving away from vaccine mandates for all citizens, while the governors of the three West coast states are conflating “science” with “ideology” while pining for a Covid-era-style CDC. In trans land: comedy writer Graham Linehan was arrested for saying mean things on-line, while trans-activists are not arrested when they threaten to kick and punch those who don't believe that men can become women. We explore the mental illness of trans-deluded people, and discuss Vivian Wilson, Elon Musk's oldest son, who thinks he's a girl.*****Our sponsors:Timeline: Accelerate the clearing of damaged mitochondria to improve strength and endurance: Go to http://www.timeline.com/darkhorse and use code darkhorse for 10% off your order.Manukora: the most flavorful, delicious, and nutritious honey you'll ever have. Get $25 off your starter kit at http://www.Manukora.com/DarkHorseSundays: Dog food so tasty and healthy, even husbands swear by it. Go to http://www.sundaysfordogs.com/DARKHORSE to receive 35% off your first order.*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org(Thumbnail Andrew Harnik/Getty Images)*****Mentioned in this episode:RFK before Congress: https://x.com/wallstreetapes/status/1964154838830502080WSJ on Tylenol in pregnancy: https://www.wsj.com/health/healthcare/rfk-jr-hhs-to-link-autism-to-tylenol-use-in-pregnancy-and-folate-deficiencies-e3acbb4cWestern Health Alliance: https://apps.oregon.gov/oregon-newsroom/OR/GOV/Posts/Post/oregon-washington-and-california-form-western-health-allianceDoyle on Linehan arrest in UnHerd: https://unherd.com/2025/09/the-shameful-arrest-of-graham-linehan/Punch TERFs: https://x.com/babybeginner/status/1963504508509593772Good genetics: https://x.com/hazelappleyard_/status/1963315154277593109Vivian Wilson in NY Mag: https://www.thecut.com/article/vivian-wilson-elon-musk-daughter-2025-fall-fashion-issue-cover-story.htmlSupport the show